Enhancing the Cytotoxic Anti-Tumor Activity of iNK Cell Therapy Using a Flex-NK™ Cell Engager

Time: 4:30 pm
day: Day 1 Track 1 PM


  • Flex NK Cell Engager antibodies redirect NK cells to kill target tumor cells
  • Flex NK cell Engager antibodies enhance the cytotoxicity of PBNK cells as well as iPSC derived NK cells (iNKs)
  • Pre-clinical data supports initiation of clinical trials in both hematological malignancies and solid tumors